Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail and Poster Display session

75P - U-PRO-CRM: Designing patient-centred dose-finding trials with patient-reported outcomes

Date

26 Feb 2024

Session

Cocktail and Poster Display session

Topics

Cancer Care Equity Principles and Health Economics

Tumour Site

Presenters

Christina Yap

Citation

Annals of Oncology (2024) 9 (suppl_1): 1-4. 10.1016/esmoop/esmoop102302

Authors

C. Yap1, E. Alger1, S. Lee2, Y.K. Cheung2

Author affiliations

  • 1 Clinical Trials Biostatistics Department, ICR - The Institute of Cancer Research - North Site, SM2 5NG - Sutton/GB
  • 2 Department Of Biostatistics, Columbia University, 10032 - New York/US

Resources

This content is available to ESMO members and event participants.

Abstract 75P

Background

The determination of a Maximum Tolerated Dose (MTD) remains the main objective for most dose-finding oncology trials. Whilst many dose-finding trials rely on clinicians to identify dose-limiting toxicities (DLTs), research has suggested that clinicians may under-report patient's adverse events. Current practice may be vulnerable to recommending intolerable doses to patients for further investigation in subsequent trials. There is increasing interest in patients self-assessing their own symptoms using Patient-reported Outcomes (PROs) in dose-finding trials. However currently, only two trial designs incorporate PROs formally in dose-escalation decision making: PRO-CRM and TiTE-PRO-CRM.

Methods

We detail the novel trial design, Utility-PRO-Continual Reassessment Method (U-PRO-CRM). This design simultaneously utilises both clinician and patient assessed DLTs to make dose escalation and de-escalation decisions and to recommend a MTD that optimises the clinician-patient DLT trade-off. U-PRO-CRM also contains PRO-CRM as a special case. We present a simulation study evaluating the performance of the U-PRO-CRM design.

Results

The U-PRO-CRM outperforms PRO-CRM in the simulation study; both when we emulate the PRO-CRM decision rule, and when we look to tailor the balance between the DLT rates reported by clinicians and those reported directly by patients. For instance, U-PRO-CRM is superior in scenarios where we look to compromise the optimal P-DLT rate given a dose’s corresponding C-DLT rate. Compared to PRO-CRM, in the majority of scenarios, U-PRO-CRM recommends the MTD more often and allocates a greater mean proportion of patients to the MTD whilst still maintaining a similar level of overdosing.

Conclusions

U-PRO-CRM generalises PRO-CRM, offering additional flexibility to define a trade-off between the risk of patient and clinician DLTs when we look to find an optimal dose. Continued patient engagement efforts can assist trialists in refining this trade-off. Patient-centric dose-finding approaches which incorporate PROs are likely to play an increasingly pivotal role in advancing our understanding of treatment tolerability, holding substantial implications for the future of early phase trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Institute of Cancer Research.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.